Literature DB >> 1419473

Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

R J MacFadyen1, K R Lees, J L Reid.   

Abstract

1. Intravenous ACE inhibitor therapy is of increasing importance in the treatment of patients with unstable heart failure after myocardial infarction. Available pharmacokinetic and concentration effect data with this route of administration are limited. 2. The pharmacokinetics and blood pressure responses to perindoprilat were studied during prolonged low dose (1 mg) infusions in eight normotensive salt replete male volunteers. 3. Subjects received randomised, single (subject) blinded therapy with saline placebo (30 ml) over 3 h or active treatment (1 mg in 30 ml) over 1 h, 3 h or 6 h by constant rate infusion. 4. Significant falls in blood pressure greater than placebo were noted with active infusions without changes in heart rate. Mean maximal plasma perindoprilat concentrations reflected the rate of infusion (1 h, 51.5 +/- 11.4 ng ml-1; 3 h, 30.4 +/- 8.4 ng ml-1; 6 h 19.0 +/- 4.0 ng ml-1) and mean maximal plasma ACE inhibition was less with slower infusions (1 h, 95.7 +/- 0.5%; 3 h 92.3 +/- 2.7%; 6 h 87.4 +/- 5.1%, P less than 0.013). 5. Concentration-time profiles showed a sigmoid drug accumulation profile with delay in the early accumulation of drug particularly during the 3 h and 6 h infusions. The pharmacokinetic data was assessed by statistical comparison of a hierarchy of standard compartmental models and non linear saturable binding models. A non linear model incorporating elements to describe both tissue and plasma binding of the drug provided the best fit to observed data. 6. Low dose constant rate infusions are a means of optimising intravenous ACE inhibitor therapy to allow individual dose titration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419473      PMCID: PMC1381527          DOI: 10.1111/j.1365-2125.1992.tb04119.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.

Authors:  S G Chiknas
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

2.  ACE inhibitors--a cornerstone of the treatment of heart failure.

Authors:  E Braunwald
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.

Authors:  W Linz; R Henning; B A Schölkens
Journal:  J Hypertens Suppl       Date:  1991-12

Review 4.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

5.  Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.

Authors:  N Sharpe; H Smith; J Murphy; S Greaves; H Hart; G Gamble
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

6.  Activation of inactive plasma renin by plasma and tissue kallikreins.

Authors:  F H Derkx; H L Tan-Tjiong; A J Man in 't Veld; M P Schalekamp; M A Schalekamp
Journal:  Clin Sci (Lond)       Date:  1979-10       Impact factor: 6.124

7.  Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.

Authors:  G P Reams; S M Lal; J J Whalen; J H Bauer
Journal:  J Clin Hypertens       Date:  1986-09       Impact factor: 3.738

8.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

9.  Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1991-09

10.  A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction.

Authors:  E G Nabel; E J Topol; A Galeana; S G Ellis; E R Bates; S W Werns; J A Walton; D W Muller; M Schwaiger; B Pitt
Journal:  J Am Coll Cardiol       Date:  1991-02       Impact factor: 24.094

View more
  5 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

3.  Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1993-04

4.  Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 5.  Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

Authors:  R J MacFadyen; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.